Clinical trials: NSCLC (non-small Cell Lung Cancer)
Non Small Cell Lung Cancer
20K Distributed Learning Challenge
Machine learn a predictive model from more than 20.000 non-small cell lung cancer patients from more than 5 health care providers from more than 5 countries.
- Trial name
- NCT03564457
- Testing
- No interventions will take place (observational)
- Where
- Netherlands
- Volunteers
- 20,000 people
- Sponsor
- Maastricht Radiation Oncology
Non-small Cell Lung Cancer (NSCLC)
A Real World Study of Mobocertinib in Adults With Lung Cancer in China (MEANING)
The main aim of this study is to learn about the time from start of mobocertinib to end of treatment with mobocertinib for any reason in Chinese adults with lung cancer who carry a certain gene mutation (epidermial growth factor…
- Trial name
- MEANING-20 (NCT05863819)
- Testing
- No Intervention
- Where
- China
- Sponsor
- Takeda
Non-Squamous Non-Small Cell Lung Cancer
A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.
This study will assess the prevalence of epidermal growth factor receptor (EGFR) mutations in newly diagnosed patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
- Trial name
- NCT01250119
- Testing
- erlotinib [Tarceva]
- Where
- 22 sites in United Kingdom
- Volunteers
- 688 people
- Sponsor
- Hoffmann-La Roche
Non-Small-Cell Lung Carcinoma, Carcinoma, Non-Small Cell Lung
Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC
The purpose of this study is to evaluate the safety and efficacy of entinostat in combination with erlotinib in the treatment of Advanced Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT00602030
- Testing
- Entinostat, Erlotinib
- Where
- 30 sites in United States
- Volunteers
- 141 people
- Sponsor
- Syndax Pharmaceuticals
NSCLC, EGFR Gene Amplification
Combination of Metformin With Gefitinib to Treat NSCLC
The purpose of this study is to determine whether metformin in combination with gefitinib are effective in patients with previously untreated advanced or metastatic Non-Small-Cell Lung cancer with epidermal growth factor receptor…
- Conditions
- NSCLC, EGFR Gene Amplification, Advanced Cancer, Stage IIIB NSCLC
- Trial name
- CGMT (NCT01864681)
- Testing
- Gefitinib and Metformin
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Recurrent Non-Small Cell Lung Carcinoma, Stage III Non-Small Cell Lung Cancer
Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
The purpose of this study is to find the benefits of combining nivolumab with metformin in advanced non-small cell lung cancer with and without prior treatment with immunotherapy.
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage III Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
- Trial name
- NCT03048500
- Testing
- Laboratory Biomarker Analysis, Metformin Hydrochloride, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Northwestern University
Lung Cancer
Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy such as gemcitabine, carboplatin, and paclitaxel use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00054392
- Testing
- carboplatin, gemcitabine hydrochloride, paclitaxel
- Where
- 57 sites in United States
- Sponsor
- Fox Chase Cancer Center
Non Small Cell Lung Cancer
Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer
This is a randomized single-institution, phase II, open-label clinical trial of neoadjuvant pembrolizumab with or without low-dose stereotactic radiation therapy (SRT) in stage I-IIIA non-small lung cancer (NSCLC) patients who…
- Trial name
- NCT03217071
- Testing
- Pembrolizumab, stereotactic radiation therapy (SRT), Surgery (Non-interventional, standard of care)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Sue Yom
Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
This phase IV trial is evaluating whether morning versus afternoon administration of standard of care immunotherapy impacts its effectiveness in treating patients with solid tumors that may have spread from where it first started…
- Conditions
- Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Lung Non-Small Cell Carcinoma
- Trial name
- NCT07405086
- Testing
- Biospecimen Collection, Immune Checkpoint Inhibitor
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- OHSU Knight Cancer Institute
Non Small Cell Lung Cancer
The Value of Surgical Mediastinal Staging in Clinical N1 Lung Cancer
In case of PET or CT based cN1 (suspected) NSCLC, ESTS guidelines propose mediastinal staging by echo-endoscopy OR mediastinoscopy.
- Trial name
- ASTER3 (NCT02222194)
- Where
- 10 sites in Belgium, France and 4 more
- Volunteers
- 105 people
- Sponsor
- Johnny Moons
Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
Background: Surgery is the primary treatment for non-small cell lung cancer (NSCLC) that is diagnosed in its earlier stages. But the tumors often return.
- Conditions
- Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinomas
- Trial name
- NCT05642195
- Testing
- Montanide (Registered Trademark) ISA-51 VG Adjuvant, H1299 Cell Lysates, N-803
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
Researchers are looking for new ways to treat locally advanced non-small cell lung cancer (NSCLC) that is unresected and has a gene mutation called KRAS G12C.
- Trial name
- NCT07554339
- Testing
- Calderasib, Durvalumab
- Where
- 107 sites in United States, Argentina and 16 more
- Volunteers
- 310 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Lung Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma
Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer
This study evaluates the side effects of pembrolizumab with or without chemotherapy in treating patients with stage IV non-small cell lung cancer that has come back after a period of improvement (recurrent) and may have spread…
- Conditions
- Metastatic Lung Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Lung Non-Small Cell Carcinoma
- Trial name
- NCT04533451
- Testing
- Pembrolizumab, Pemetrexed, Carboplatin
- Where
- 505 sites in United States
- Volunteers
- 101 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Advanced Cancer, Angiosarcoma
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) profiles of a novel fragment crystallizable (Fc)-engineered immunoglobulin G1…
- Conditions
- Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer
- Trial name
- NCT03860272
- Testing
- Botensilimab, Balstilimab
- Where
- 18 sites in United States, United Kingdom
- Volunteers
- 499 people
- Sponsor
- Agenus Inc.
Non-small Cell Lung Cancer
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
The study is being conducted to evaluate the efficacy, and safety of camrelizumab combined with famitinib malate vs. pembrolizumab in treatment naïve subjects with programmed death-ligand 1(PD-L1)-positive recurrent or metastatic…
- Trial name
- NCT05042375
- Testing
- camrelizumab + famitinib, pembrolizumab, camrelizumab
- Where
- 80 sites in China
- Volunteers
- 450 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Neurocognitive
Neurocognition in NSCLC Patients Treated With Osimertinib or Osimertinib + WBI
This is a prospective, randomised, positive-controlled, study to assess the neurocognitive function of upfront Osimertinib compared to whole-brain irradiation (WBI) plus Osimertinib in EGFR-mutant (Ex 19Del and L858R) NSCLC…
- Trial name
- NCT04829019
- Testing
- Osimertinib and whole-brain irradiation, Osimertinib
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Sun Yat-sen University
Brain and Central Nervous System Tumors, Breast Cancer
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00019019
- Testing
- carboxyamidotriazole, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Solid Tumor, Adult
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive…
- Trial name
- NCT04306900
- Testing
- TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6
- Where
- 32 sites in United States, South Korea
- Volunteers
- 185 people
- Sponsor
- Trishula Therapeutics, Inc.
Solid Tumor, Advanced Solid Tumor
A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
This is a Phase 1, open-label, multicenter, study evaluating the safety, tolerability, PK, PD, and anti-tumor activity of MRTX0902 alone and in combination with MRTX849 (adagrasib) in patients with advanced solid tumor malignancy…
- Conditions
- Solid Tumor, Advanced Solid Tumor, Non Small Cell Lung Cancer, Colo-rectal Cancer
- Trial name
- NCT05578092
- Testing
- MRTX0902, MRTX849
- Where
- 18 sites in United States, Puerto Rico
- Volunteers
- 64 people
- Sponsor
- Mirati Therapeutics Inc.
EGF-R Positive Non-Small Cell Lung Cancer, CNS Metastases
An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis
EGFR mutation positive advanced NSCLC patients with CNS metastases were associated with poor prognosis. Furmonertinib showed promising CNS efficacy in doses of 80 mg orally once daily or higher in patients with EGFR T790M…
- Trial name
- NCT06352502
- Testing
- Furmonertinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tang-Du Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.